ALVO: מכפיל P/S Alvotech Corp

The revenue valuation metric reflects the impact of biosimilar certification timelines and the capacity of the Icelandic plant, while 3.70 determines the current status of this parameter. Alvotech strategy relies on global distribution through alliances with major players, and the transition to mass sales of complex drugs creates leverage to offset previous R&D expenditures.

To identify fundamental benchmarks in Alvotech (ALVO) financial reporting, analyzing the market capitalization to annual revenue ratio is critical. The P/S ratio trend allows for an assessment of the risk of overpaying for the asset, reflecting the efficiency of biosimilar expansion: a decline in this metric on the chart may indicate either an undervalued business or the consequences of aggressive dumping to capture market niches.